Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry.
Burden of disease
Enzyme replacement therapy
HRQoL
Hypophosphatasia
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
24
08
2021
accepted:
06
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
The clinical signs and symptoms of hypophosphatasia (HPP) can manifest during any stage of life. The age at which a patient's symptoms are reported can impact access to targeted treatment with enzyme replacement therapy (asfotase alfa), as this treatment is indicated for patients with pediatric-onset HPP in most countries. As such, many patients reported to have adult-onset HPP typically do not receive treatment. Comparison of the disease in treated and untreated adult patients is confounded by the approved indication. To avoid this confounding factor, a comparison between baseline disease manifestations prominent among treated versus untreated adult patients was limited to those with pediatric-onset HPP using data collected from the Global HPP Registry. The hypothesis was that treated adults will have a greater disease burden at baseline than untreated adults. The analysis of disease manifestations in adults with adult-onset HPP was conducted separately. A total of 398 adults with HPP were included; 213 with pediatric-onset (114 treated, 99 untreated) and 141 with adult-onset HPP (2 treated and 139 untreated). The treated, pediatric-onset patients were more likely to have a history of pain (prevalence ratio [PR]: 1.3, 95% confidence interval [CI] 1.1, 1.4), skeletal (PR: 1.3, 95% CI 1.1, 1.6), constitutional/metabolic (PR: 1.7, 95% CI 1.3, 2.0), muscular (PR: 1.8, 95% CI 1.4, 2.1) and neurological (PR: 1.7, 95% CI 1.1, 2.3) manifestations of HPP, and also had poorer measures for health-related quality of life, pain, and disability compared with untreated pediatric-onset patients. In patients with adult-onset HPP, the most frequent signs and symptoms were chronic bone pain (52.5%), dental manifestations (42.6%), fatigue (23.4%), recurrent fractures or pseudofractures (22.0%), and generalized body pain (22.0%). Along with the more classical skeletal signs and symptoms, pain, muscular, and constitutional/metabolic manifestations are common in adults with HPP, regardless of age of disease onset, highlighting a full spectrum of HPP manifestations.
Sections du résumé
BACKGROUND
The clinical signs and symptoms of hypophosphatasia (HPP) can manifest during any stage of life. The age at which a patient's symptoms are reported can impact access to targeted treatment with enzyme replacement therapy (asfotase alfa), as this treatment is indicated for patients with pediatric-onset HPP in most countries. As such, many patients reported to have adult-onset HPP typically do not receive treatment. Comparison of the disease in treated and untreated adult patients is confounded by the approved indication. To avoid this confounding factor, a comparison between baseline disease manifestations prominent among treated versus untreated adult patients was limited to those with pediatric-onset HPP using data collected from the Global HPP Registry. The hypothesis was that treated adults will have a greater disease burden at baseline than untreated adults. The analysis of disease manifestations in adults with adult-onset HPP was conducted separately.
RESULTS
A total of 398 adults with HPP were included; 213 with pediatric-onset (114 treated, 99 untreated) and 141 with adult-onset HPP (2 treated and 139 untreated). The treated, pediatric-onset patients were more likely to have a history of pain (prevalence ratio [PR]: 1.3, 95% confidence interval [CI] 1.1, 1.4), skeletal (PR: 1.3, 95% CI 1.1, 1.6), constitutional/metabolic (PR: 1.7, 95% CI 1.3, 2.0), muscular (PR: 1.8, 95% CI 1.4, 2.1) and neurological (PR: 1.7, 95% CI 1.1, 2.3) manifestations of HPP, and also had poorer measures for health-related quality of life, pain, and disability compared with untreated pediatric-onset patients. In patients with adult-onset HPP, the most frequent signs and symptoms were chronic bone pain (52.5%), dental manifestations (42.6%), fatigue (23.4%), recurrent fractures or pseudofractures (22.0%), and generalized body pain (22.0%).
CONCLUSIONS
Along with the more classical skeletal signs and symptoms, pain, muscular, and constitutional/metabolic manifestations are common in adults with HPP, regardless of age of disease onset, highlighting a full spectrum of HPP manifestations.
Identifiants
pubmed: 35854311
doi: 10.1186/s13023-022-02393-8
pii: 10.1186/s13023-022-02393-8
pmc: PMC9295501
doi:
Substances chimiques
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
277Informations de copyright
© 2022. The Author(s).
Références
Endocrinol Diabetes Metab Case Rep. 2021 Sep 01;2021:
pubmed: 34515659
Bone. 2019 Apr;121:149-162
pubmed: 30576866
Osteoporos Int. 2017 Sep;28(9):2653-2662
pubmed: 28547134
J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):297-304
pubmed: 1151410
J Musculoskelet Neuronal Interact. 2021 Dec 1;21(4):584-589
pubmed: 34854399
AACE Clin Case Rep. 2019 Aug 15;5(6):e344-e348
pubmed: 31967067
Int J Mol Sci. 2021 Jan 24;22(3):
pubmed: 33498907
Clin Biochem Rev. 2020 Feb;41(1):13-27
pubmed: 32158059
Mol Genet Metab Rep. 2020 Oct 21;25:100661
pubmed: 33101980
J Bone Miner Res. 2020 Nov;35(11):2171-2178
pubmed: 32654183
J Bone Miner Res. 2017 Apr;32(4):667-675
pubmed: 28084648
Calcif Tissue Int. 2016 Apr;98(4):398-416
pubmed: 26590809
Clin Cases Miner Bone Metab. 2017 Sep-Dec;14(3):347-353
pubmed: 29354166
Science. 1988 Jan 15;239(4837):268-75
pubmed: 3276003
JBMR Plus. 2020 Aug 04;4(9):e10395
pubmed: 32995696
Bone. 2013 May;54(1):21-7
pubmed: 23352924
Orphanet J Rare Dis. 2007 Oct 04;2:40
pubmed: 17916236
J Bone Miner Res. 2012 May;27(5):987-94
pubmed: 22322541
BMC Musculoskelet Disord. 2019 Feb 14;20(1):80
pubmed: 30764793
Nat Rev Endocrinol. 2016 Apr;12(4):233-46
pubmed: 26893260
Orphanet J Rare Dis. 2019 Apr 25;14(1):85
pubmed: 31023354
Dan Med Bull. 1968 Sep;15:Suppl 2:1-112
pubmed: 4306219
Metabolism. 2016 Oct;65(10):1522-30
pubmed: 27621187
Curr Osteoporos Rep. 2016 Jun;14(3):95-105
pubmed: 27084188